|
Apr 25
|
Roche’s diagnostic sales hit by China pricing reforms
|
|
Apr 25
|
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
|
|
Apr 24
|
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
|
|
Apr 24
|
Drugmakers brace for Trump tariffs, while weighing numerous other worries
|
|
Apr 24
|
Repertoire and Genentech to develop autoimmune disease therapies
|
|
Apr 24
|
Roche introduces algorithm for ACS detection in individuals with chest pain
|
|
Apr 24
|
Roche seeks US tariff relief in direct talks with Trump administration
|
|
Apr 24
|
Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push
|
|
Apr 24
|
Roche Q1 sales up 7% on drugs Phesgo, Vabysmo
|
|
Apr 24
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter
|
|
Apr 23
|
Roche looks to a Flagship startup in search of new immune drugs
|
|
Apr 23
|
Switzerland flexes financial muscle ahead of tariff date in Washington
|
|
Apr 23
|
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
|
|
Apr 22
|
Roche says it will invest $50 billion in the U.S. as tariff fears hit pharma
|
|
Apr 22
|
Swiss Pharma Giant Roche To Invest $50B in US Amid Tariff Threat
|
|
Apr 22
|
Roche, answering tariff threat, pledges $50B to US drug production
|
|
Apr 22
|
Pharma giant plots US weight-loss drug factory
|
|
Apr 22
|
Morning Bid:'Major loser' reporting for duty
|
|
Apr 22
|
Drug Companies Step Up 'Make in America' Plans to Counter Tariffs
|
|
Apr 22
|
Swiss drugmaker Roche leans into Trump tariff formula with $50 billion promise to invest in U.S.
|